- Home
- / Reata Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
CreditSafe score
?
Score changed on Jan 30, 2023
Premium Content
Learn moreFinancial statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|
| Revenue | 48.1M | 53.6M | 26.5M | 9.0M | 11.5M |
| Revenue growth, % | -4.0% | 11.5% | -50.5% | ||
| General and administrative expense | 23.3M | 32.7M | 58.3M | 75.1M | 99.0M |
| Operating expense total | 95.0M | 130.5M | 311.7M | 234.2M | |
| Depreciation and amortization | 437.0K | 431.0K | 932.0K | 1.1M | 1.2M |
| Investment income | 701.0K | 3.5M | 6.2M | ||
| Interest expense | 1.5M | 6.2M | 11.2M | ||
| Pre tax profit | (47.7M) | (80.5M) | (290.2M) | (270.2M) | (297.8M) |
| Income tax expense | 3.0K | 26.0K | 8.0K | (22.5M) | (450.0K) |
| Net Income | (47.7M) | (80.5M) | (290.2M) | (247.8M) | (297.4M) |
| EPS | (2.0) | (2.9) | (9.5) |